Kailera Therapeutics, Inc. (NASDAQ:KLRA) Receives Average Rating of “Buy” from Brokerages

Kailera Therapeutics, Inc. (NASDAQ:KLRA) has received an average rating of “Buy” from the seven brokerages that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a hold recommendation, five have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $42.75.

Several analysts have recently issued reports on KLRA shares. Zacks Research raised shares of Kailera Therapeutics to a “hold” rating in a research note on Wednesday, May 13th. TD Cowen began coverage on Kailera Therapeutics in a report on Tuesday, May 12th. They issued a “buy” rating and a $57.00 target price on the stock. JPMorgan Chase & Co. began coverage on Kailera Therapeutics in a research report on Tuesday, May 12th. They set an “overweight” rating and a $30.00 price target for the company. William Blair began coverage on Kailera Therapeutics in a research note on Tuesday, May 12th. They set an “outperform” rating for the company. Finally, Leerink Partners initiated coverage on Kailera Therapeutics in a report on Tuesday, May 12th. They issued an “outperform” rating and a $36.00 price objective on the stock.

Insider Transactions at Kailera Therapeutics

In other Kailera Therapeutics news, major shareholder Rtw Investments, Lp purchased 500,000 shares of Kailera Therapeutics stock in a transaction on Monday, April 20th. The shares were purchased at an average cost of $16.00 per share, with a total value of $8,000,000.00. Following the completion of the transaction, the insider directly owned 10,776,820 shares in the company, valued at approximately $172,429,120. This represents a 4.87% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Andrew T. Kaplan purchased 8,398,438 shares of Kailera Therapeutics stock in a transaction on Monday, April 20th. The shares were acquired at an average cost of $16.00 per share, for a total transaction of $134,375,008.00. Following the completion of the transaction, the director owned 26,255,581 shares of the company’s stock, valued at $420,089,296. This represents a 47.03% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last quarter, insiders bought 10,460,938 shares of company stock worth $167,375,008.

Kailera Therapeutics Stock Performance

Shares of KLRA stock opened at $22.24 on Wednesday. The stock has a market cap of $2.88 billion and a price-to-earnings ratio of -0.01. Kailera Therapeutics has a 1-year low of $18.50 and a 1-year high of $28.23. The business’s 50-day moving average is $21.49.

Kailera Therapeutics (NASDAQ:KLRA) last released its earnings results on Tuesday, May 26th. The company reported ($3,650.00) earnings per share (EPS) for the quarter.

Kailera Therapeutics Company Profile

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.